SPY322.12+3.20 1.00%
DIA268.78+2.19 0.82%
IXIC10,565.84+77.27 0.74%
News
IDYA
--
0.00%
--
IDEAYA to Participate in Fireside Chat at BTIG Biotechnology Conference and Wedbush PacGrow Healthcare Conference on August 11 and 12, 2020
IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced the Company will participate in the following upcoming investor conferences:
PR Newswire · 1d ago
80 Biggest Movers From Yesterday
Gainers Equillium, Inc. (NASDAQ: EQ) shares surged 730.7% to close at $26.50 on Monday after the company disclosed that Itolizumab significantly reduced mortality in coronavirus patients, according to a clinical trial conducted in India by its partner Biocon.
Benzinga · 1d ago
JP Morgan Upgrades IDEAYA Biosciences to Overweight, Announces $28 Price Target
JP Morgan analyst Anupam Rama upgrades IDEAYA Biosciences (NASDAQ:IDYA) from Neutral to Overweight and announces $28 price target.
Benzinga · 2d ago
IDEAYA launches early-stage study of IDE196 in eye cancer
IDEAYA Biosciences (IDYA -2.4%) has dosed the first patient in a Phase 1 clinical trial evaluating the combination of IDE196, a protein kinase C inhibitor
seekingalpha · 5d ago
IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Binimetinib, a MEK Inhibitor
IDEAYA Biosciences, Inc. (NASDAQ: IDYA)IDEAYA Biosciences, Inc.
Benzinga · 6d ago
IDEAYA Biosciences Reports Dosing Of First Patient In Phase 1 Combo Study Of IDE196, Binimetinib For Metastatic Uveal Melanoma
Benzinga · 6d ago
IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Binimetinib, a MEK Inhibitor
IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced First-Patient-In (FPI) in the Phase 1 combination study of IDE196 and binimetinib, a MEK inhib
PR Newswire · 6d ago
Boxer Capital Reports 7.8% Passive Stake in Ideaya Biosciences as of June 19
-13G
13G · 06/30 10:35
IDEAYA Appoints Garret Hampton, Ph.D., to the Board of Directors, an Industry Leader in Precision Medicine Oncology and Diagnostics
IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics based on Synthetic Lethality, announced the appointment of Garret Hampton, Ph.D., to its Board of Directo
PR Newswire · 06/30 10:00
Repare and Forma Shares Gobbled Up in IPO
GuruFocus.com · 06/22 21:35
NES, ISEE, QUIK and BBI among midday movers
Seeking Alpha - Article · 06/18 16:44
Morning Market Stats in 5 Minutes
Movers Indices • S&P 500 ETF (NYSE:SPY) decreased 0.56% to $309.82. • Nasdaq ETF (NASDAQ:QQQ) fell 0.14% to $243.28. • Dow Jones Industrial Average ETF (NYSE:DIA) fell 0.79% to $259.82.
Benzinga · 06/18 13:53
SSL, CCL among premarket losers
Seeking Alpha - Article · 06/18 12:51
The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 17)
Benzinga · 06/18 12:34
IDEAYA Prices 6.6M Share Public Offering of Common Stock @$15.50/Share
IDEAYA Biosciences, Inc.(NASDAQ: IDYA) today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at a public offering price of $15.00 per share, before underwriting discounts and commissions.
Benzinga · 06/18 10:23
Ideaya prices equity offering at $15
Seeking Alpha - Article · 06/18 08:46
IDEAYA Announces Pricing of Public Offering of Common Stock
PR Newswire · 06/18 02:34
Repare Therapeutics files for upsized IPO
Seeking Alpha - Article · 06/17 20:52
Biotech Stock Roundup: REGN Begins Coronavirus Study, VRTX, BIIB Give Updates
Zacks · 06/17 14:53
HC Wainwright & Co. Maintains Buy on IDEAYA Biosciences, Raises Price Target to $22
HC Wainwright & Co. maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and raises the price target from $13 to $22.
Benzinga · 06/17 10:04